5-Fluorouracil ethosomes – skin deposition and melanoma permeation synergism with microwave
Source abstract
Abstract
This study focuses on the use of ethosome and microwave technologies to facilitate skin penetration and/or deposition of 5-fluorouracil in vitro and in vivo. Low ethanol ethosomes were designed and processed by mechanical dispersion technique and had their size, zeta potential, morphology, drug content and encapsulation efficiency characterized. The skin was pre-treated with microwave at 2450 MHz for 2.5 min with ethosomes applied topically and subjected to in vitro and in vivo skin drug permeation as well as retention evaluation. The drug and/or ethosomes cytotoxicity, uptake and intracellular trafficking by SKMEL-28 melanoma cell culture were evaluated. Pre-treatment of skin by microwave promoted significant drug deposition in skin from ethosomes in vitro while keeping the level of drug permeation unaffected. Similar observations were obtained in vivo with reduced drug permeation into blood. Combination ethosome and microwave technologies enhanced intracellular localization of ethosomes through fluidization of cell membrane lipidic components as well as facilitating endocytosis by means of clathrin, macropinocytosis and in particularly lipid rafts pathways. The synergistic use of microwave and ethosomes opens a new horizon for skin malignant melanoma treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Skin and Cellular Biology Research · Dermatology and Skin Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Non-Destructive Biomedical and Pharmaceutical Research Centre, iPROMISE
Particle Design Research Group, Faculty of Pharmacy, Universiti Teknologi MARA Selangor
Funding
MOSTI · MOHE · IRMI · UiTM
References (50)
Show source-provided references
1. 10.1016/j.ijscr.2013.10.01410.1016/j.ijscr.2013.10.014 ↗
2. 10.1111/j.1365-4632.2010.04474.x10.1111/j.1365-4632.2010.04474.x ↗
3. 10.1038/ncponc088310.1038/ncponc0883 ↗
4. 10.1016/j.ejps.2015.06.01310.1016/j.ejps.2015.06.013 ↗
5. 10.1016/j.clindermatol.2013.08.02010.1016/j.clindermatol.2013.08.020 ↗
6. 10.1007/s10637-011-9717-210.1007/s10637-011-9717-2 ↗
7. 10.1016/j.ijpharm.2012.06.00510.1016/j.ijpharm.2012.06.005 ↗
8. 10.2174/138161282166615042814521610.2174/1381612821666150428145216 ↗
9. 10.3109/10717544.2014.97689110.3109/10717544.2014.976891 ↗
10. 10.1016/j.ijbiomac.2014.03.01110.1016/j.ijbiomac.2014.03.011 ↗
11. 10.1016/j.ijpharm.2013.11.01710.1016/j.ijpharm.2013.11.017 ↗
12. 10.1016/j.apsb.2015.09.00610.1016/j.apsb.2015.09.006 ↗
13. 10.1016/j.colsurfb.2015.07.07810.1016/j.colsurfb.2015.07.078 ↗
14. 10.1016/j.addr.2015.12.00210.1016/j.addr.2015.12.002 ↗
15. 10.1124/pr.58.1.810.1124/pr.58.1.8 ↗
16. 10.1016/j.polymer.2016.05.05110.1016/j.polymer.2016.05.051 ↗
17. 10.1016/j.jhazmat.2016.06.02310.1016/j.jhazmat.2016.06.023 ↗
18. 10.1016/j.ijpharm.2015.10.04910.1016/j.ijpharm.2015.10.049 ↗
19. 10.1016/j.bbamem.2016.04.01410.1016/j.bbamem.2016.04.014 ↗
20. 10.1016/j.bbamem.2016.06.02410.1016/j.bbamem.2016.06.024 ↗
21. 10.1016/j.algal.2016.02.01710.1016/j.algal.2016.02.017 ↗
22. 10.1016/j.ultrasmedbio.2015.06.00610.1016/j.ultrasmedbio.2015.06.006 ↗
23. 10.1016/j.ijpharm.2010.09.00810.1016/j.ijpharm.2010.09.008 ↗
24. 10.1016/j.jfoodeng.2004.04.01710.1016/j.jfoodeng.2004.04.017 ↗
25. 10.1111/j.1463-1318.2010.02323.x10.1111/j.1463-1318.2010.02323.x ↗
26. 10.1093/bmb/ldm02010.1093/bmb/ldm020 ↗
27. 10.1016/S0002-9610(05)80013-310.1016/S0002-9610(05)80013-3 ↗
28. Jacob C. Treatment of hyperhidrosis with microwave technology. Semin Cutan Med Surg. 2013;32:2–8.
29. 10.1016/j.ijpharm.2008.01.04710.1016/j.ijpharm.2008.01.047 ↗
30. 10.1208/pt07011510.1208/pt070115 ↗
31. 10.1016/j.jpba.2006.08.01410.1016/j.jpba.2006.08.014 ↗
32. 10.1016/j.ijbiomac.2014.01.03410.1016/j.ijbiomac.2014.01.034 ↗
33. 10.1007/s11095-012-0852-z10.1007/s11095-012-0852-z ↗
34. 10.1080/17425247.2016.119315210.1080/17425247.2016.1193152 ↗
35. 10.1016/S0168-3659(99)00222-910.1016/S0168-3659(99)00222-9 ↗
36. 10.1016/j.fct.2011.03.03310.1016/j.fct.2011.03.033 ↗
37. 10.1016/j.cmpb.2010.01.00710.1016/j.cmpb.2010.01.007 ↗
38. 10.1016/j.ijpharm.2014.04.00610.1016/j.ijpharm.2014.04.006 ↗
39. 10.2147/IJN.S6280610.2147/IJN.S62806 ↗
40. 10.1016/j.ejpb.2012.02.00810.1016/j.ejpb.2012.02.008 ↗
41. 10.1016/j.ijpharm.2007.11.03710.1016/j.ijpharm.2007.11.037 ↗
42. 10.1016/j.biomaterials.2010.08.08110.1016/j.biomaterials.2010.08.081 ↗
43. 10.1093/nar/gkh59510.1093/nar/gkh595 ↗
44. 10.4155/tde.12.11810.4155/tde.12.118 ↗
45. 10.1016/S0923-1811(03)00038-010.1016/S0923-1811(03)00038-0 ↗
46. 10.1038/nrm233010.1038/nrm2330 ↗
47. 10.1021/ed078p125110.1021/ed078p1251 ↗
48. 10.1083/jcb.123.5.110710.1083/jcb.123.5.1107 ↗
49. 10.1128/MCB.16.4.172210.1128/MCB.16.4.1722 ↗
50. 10.1042/bj2003125310.1042/bj20031253 ↗